- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02435056
Medication Overuse Headache (MOH) and an Innovative Approach (COMOESTAS)
Continuous Monitoring of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It will be a multicentre parallel group study. The two arms of the clinical protocol will be 1) classic approach to MOH and 2) Interactive Electronic Patient Record (IEPR)-based approach to MOH.
Each arm will last 12 months.
MOH will be diagnosed according to the 2006 MOH-R criteria of the International Headache Society as reported below:
A. Headache present on > 15 days/month.
B. Regular overuse for > 3 months of one or more acute symptomatic drugs:
- Ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month on a regular basis for > 3 months.
- Simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month on a regular basis for >3 months without overuse (> 10 days) of any single class alone.
C. Headache has developed or markedly worsened during medication overuse.
The IEPR approach will be preliminarily tested and validated in small groups of patients during months 6-12 (pilot validation).
Each patient will be evaluated over a period of 7 months.
Classic approach Visit 0: patient is examined and, if suspected to suffer from MOH, is asked to fill in a diary for a month in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.). Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.
Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH-R diagnosis are fulfilled and exclusion criteria are ruled out , patient is enrolled in COMOESTAS protocol.
Detoxification: following visit 1, patient undergoes detoxification according to the protocol in Appendix 1. In the subsequent 2 months the patient is instructed to record headache characteristics and consumption of symptomatic drugs on a paper diary.
Visit 2 (2 months after detoxification): patient is visited again; diary is checked; if therapy is successful (patient no longer overuses acute medications for headache) the patient is scheduled for a follow-up visit after 4 months. The patient is asked to keep up recording headache characteristics and consumption of symptomatic drugs on a paper diary for the next 4 months and informed about a telephone contact after 2 months.
Visit 3 (6 months after detoxification): patient is visited again, diary data are collected. Study ends.
IEPR approach Visit 0: patient is examined and, if the minimum data set of the IEPR for MOH is satisfied, the patients is asked to record the headache characteristics as well as acute drugs consumption on a paper diary for a month in order to assess baseline parameters of MOH (days with headache, acute drugs consumed, etc.).
Patient has to report that MOH-R criteria were fulfilled for the previous 2 months.
Visit 1: Patient returns to the Centre, diary data are analyzed and recorded, and, if criteria for MOH diagnosis are confirmed and criteria of exclusion are ruled out, patient is enrolled in COMOESTAS protocol .
Detoxification: following Visit 1, patient undergoes detoxification according to the same protocol adopted for the classic approach. During the detoxification phase, the patient is instructed to use the electronic diary and is then asked to fill the electronic diary on a regular basis (preferably daily or at least weekly) for the next 6 months.
Visit 2 (2 months after detoxification): patient is visited again; if therapy is successful (patient no longer overuses acute medications for headache), MOH diagnosis the patient is scheduled for a follow-up visit after 4 months and informed about a telephone contact after 2 months. The patient is asked to keep up filling the electronic diary for the next 4 months.
Visit 3: the patient is visited again. Study ends.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with MOH
Exclusion Criteria:
- a current diagnosis of co-existent, significant and complicating medical or psychiatric illnesses
- significant overuse of "pure" opioids (patients overusing combination drugs containing opioids are allowed), benzodiazepines, and barbiturates,
- overuse of alcohol and other drugs of addiction,
- current treatment with migraine prophylactic drugs
- inefficacy of previous adequate detoxification programmes
- inability to provide reliable information about medical history
- pregnancy or breast feeding
- inability to learn how to use paper or electronic diaries
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Classic Approach
Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
|
|
Experimental: IEPR Approach
Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
|
Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse Rate Follow up
Time Frame: 6 month
|
Relapse Rate 6 months after withdrawal of patients with medication overuse.
Relapse will be defined as use of ergotamine, triptans, opioids or combination analgesic medications on > 10 days/month or use of simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on > 15 days/month during the previous month, with the exclusion of month +1.
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days with headache
Time Frame: 6 month
|
Number of days with headache before and after detoxification in the two arms (month -1 vs. month +6)
|
6 month
|
Days per month with migraine
Time Frame: 6 month
|
Number of days per month with migraine before and after detoxification in the two arms (month -1 vs. month +6)
|
6 month
|
MOH patients/total number of headache
Time Frame: 12 month
|
Number of MOH patients/total number of headache patients during the recruitment period (6-12 months ) of the two arms
|
12 month
|
MOH patients/total number of headache
Time Frame: 24 month
|
Number of MOH patients/total number of headache patients during the recruitment period (18-24 months ) of the two arms
|
24 month
|
Drop-outs
Time Frame: 24 month
|
Number of drop-outs in the two arms
|
24 month
|
Midas scores
Time Frame: 24 month
|
Changes in Midas scores in the two arms
|
24 month
|
HURT scores
Time Frame: 24 month
|
Changes in HURT scores in the two arms
|
24 month
|
Collaborators and Investigators
Investigators
- Study Director: Giuseppe Nappi, MD, IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia, ITALY
- Principal Investigator: Rigmor Jensen, MD, PhD, Glostrup Hospital, Copenaghen, Denmark
- Principal Investigator: Zaza Katsarava, MD, PHD, MSc, Universitaetsklinikum, Essen, Germany
- Principal Investigator: Jorge Leston, MD, Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia, Argentina
- Principal Investigator: Ricardo Fadic, MD, Pontificia Universidad Catolica de Chile
- Principal Investigator: Miguel JA Lainez, MD, PhD, Fundacion de la Comunidad Valenciana para la Investigacion Biomedica, la Docencia Y la Cooperacion Internacional y para el Desarrollo del Hospital Clinico Universitario De Valencia, Spain
- Principal Investigator: Marco Pagani, Manager, Consorzio di Bioingegneria Medica, Pavia, Italy
- Principal Investigator: Nestor Gorini, Ministerio de la Salud de la Provincia de Buenos Aires, Argentina
- Principal Investigator: Santiago Spadafora, Fundacion Isalud, Buenos Aires, Argentina
Publications and helpful links
General Publications
- Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004 Aug;3(8):475-83. doi: 10.1016/S1474-4422(04)00824-5.
- Headache Classification Committee; Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 Jun;26(6):742-6. doi: 10.1111/j.1468-2982.2006.01172.x.
- Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006 Sep;26(9):1097-105. doi: 10.1111/j.1468-2982.2006.01175.x.
- Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006 Oct;26(10):1192-8. doi: 10.1111/j.1468-2982.2006.01190.x.
- Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006 Jun 27;66(12):1894-8. doi: 10.1212/01.wnl.0000217914.30994.bd. Epub 2006 May 17.
- Haag G, Baar H, Grotemeyer KH, Pfaffenrath V, Ribbat MJ, Diener HC. [Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache]. Schmerz. 1999 Feb 18;13(1):52-7. doi: 10.1007/s004829900016. No abstract available. German.
- Jellestad PL, Carlsen LN, Westergaard ML, Munksgaard SB, Bendtsen L, Lainez M, Fadic R, Katsarava Z, Goicochea MT, Spadafora S, Jensen RH, Nappi G, Tassorelli C; COMOESTAS Consortium. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project. Cephalalgia. 2019 Feb;39(2):274-285. doi: 10.1177/0333102418786265. Epub 2018 Jul 8. Erratum In: Cephalalgia. 2019 Oct;39(11):1472.
- Tassorelli C, Jensen R, Allena M, De Icco R, Katsarava Z, Miguel Lainez J, Leston JA, Fadic R, Spadafora S, Pagani M, Nappi G; COMOESTAS Consortium. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2017 Oct;37(12):1115-1125. doi: 10.1177/0333102416660549. Epub 2016 Jul 20.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 215366
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Overuse Headache
-
Hospital of South West JutlandCompletedMedication-overuse Headache | Secondary Headache Disorders
-
Danish Headache CenterCompletedMedication-overuse HeadacheDenmark
-
University Hospital, AkershusUniversity of OsloCompletedChronic Headache | Medication-overuse HeadacheNorway
-
Wei DaiInternational Headache SocietyRecruitingMigraine Disorders | Medication-overuse HeadacheChina
-
University of CalgaryAlberta Health servicesCompletedMedication Overuse Headache | Analgesic Overuse HeadacheCanada
-
H. Lundbeck A/SRecruitingMigraine | Medication Overuse HeadacheSpain, Italy, United States, Denmark, France, Netherlands, Australia, Georgia, Germany, Norway, Sweden
-
AmgenCompletedMigraine HeadacheUnited States, Austria, Australia, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
-
Diskapi Teaching and Research HospitalActive, not recruitingMedication Overuse HeadacheTurkey
-
Norwegian University of Science and TechnologyCompleted
-
Sorlandet Hospital HFCompleted
Clinical Trials on IEPR Approach
-
University of Sao Paulo General HospitalUniversity of Campinas, BrazilUnknown
-
Sahlgrenska University Hospital, SwedenVastra Gotaland RegionRecruitingMuscle Weakness | Muscle Atrophy | Hip Osteoarthritis | Arthroplasty Complications | Muscle InjurySweden
-
Iuliu Hatieganu University of Medicine and PharmacyEmergency County Hospital Cluj-NapocaCompleted
-
Florida Orthopaedic InstituteOrthopaedic Trauma AssociationCompletedTibial FracturesUnited States
-
Medacta USAMedacta International SACompletedOsteoarthritisUnited States
-
Seoul National University Bundang HospitalCompletedArthroplasty, Replacement, HipKorea, Republic of
-
Sorlandet Hospital HFUnknown
-
Fraser Orthopaedic Research SocietyCompletedINfrapatellar Versus SUprapatellar Reamed Intramedullary Nailing for Fractures of the Tibia (INSURT)Tibial Fractures | Anterior Knee Pain SyndromeCanada, Spain
-
Cairo UniversityCompletedFacial Nerve Injuries | Subcondylar Process of Mandible Open FractureEgypt
-
Assiut UniversityUnknown